Skip to main content
Erschienen in: Clinical Research in Cardiology 8/2010

01.08.2010 | Original Paper

Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis

Erschienen in: Clinical Research in Cardiology | Ausgabe 8/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Amyloid light chain (AL) amyloidosis is a rare disease with poor prognosis and limited therapeutic alternatives. Recently, one clinical case with cardiac involvement, as well as a compelling evidence of green tea polyphenol, epigallocatechin-3-gallate (EGCG), inducing the formation of benign aggregation products that do not polymerize into fibrils were published. This is a report of the cardiac effects of green tea consumption in these patients.

Methods

Patients with known cardiac involvement in AL amyloidosis were examined by routine cardiovascular examinations that took place every 3–6 months. Of 59 patients with cardiac involvement, 11 revealed a decrease of at least 2 mm of interventricular wall thickness, after initiation of regular green tea consumption (GT). A matched historic control group (n = 22) was selected. Comprehensive echocardiography was conducted at every control examination and analyzed offline by two independent examiners.

Results

GT patients showed an improvement in New York Heart Association (NYHA) class from a median of 3 (25th, 75th percentiles: 2, 3) to 2 (2, 3), P = 0.038. Septal thickness decreased from 18 (18, 20) to 16 (16, 17) mm, P = 0.021. Left ventricular mass index decreased from 175 (154, 180) to 133 (128, 154) g/m2, P = 0.007. Comparing both groups, an increase in left ventricular ejection fraction could be found in the GT group, 65 (51, 73) versus 53 (47, 59)%, P = 0.012. These changes could not be observed in the control group.

Conclusion

Consumption of green tea polyphenol EGCG in patients with cardiac involvement with AL amyloidosis causes a significant decrease in left ventricular wall thickness and mass, as well as an improvement in NYHA functional classification and left ventricular ejection fraction.
Literatur
1.
Zurück zum Zitat Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 79:319–328CrossRefPubMed Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 79:319–328CrossRefPubMed
2.
Zurück zum Zitat Gertz MA, Lacy MG, Dispenzieri A (2004) Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev 18:17–37CrossRefPubMed Gertz MA, Lacy MG, Dispenzieri A (2004) Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev 18:17–37CrossRefPubMed
3.
Zurück zum Zitat Roig E, Almenar L, González-Vílchez F et al (2009) Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. Am J Transplant 9:1414–1419CrossRefPubMed Roig E, Almenar L, González-Vílchez F et al (2009) Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. Am J Transplant 9:1414–1419CrossRefPubMed
4.
Zurück zum Zitat Hunstein W (2007) Epigallocatechin-3-gallate in AL amyloidosis: a new therapeutic option? Blood 110:2216CrossRefPubMed Hunstein W (2007) Epigallocatechin-3-gallate in AL amyloidosis: a new therapeutic option? Blood 110:2216CrossRefPubMed
5.
Zurück zum Zitat Shammas MA, Neri P, Koley H et al (2006) Specific killing of multiple myeloma cells by (−)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood 108:2804–2810CrossRefPubMed Shammas MA, Neri P, Koley H et al (2006) Specific killing of multiple myeloma cells by (−)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood 108:2804–2810CrossRefPubMed
6.
Zurück zum Zitat Shanafelt TD, Lee YK, Call TG et al (2006) Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res 30:707–712CrossRefPubMed Shanafelt TD, Lee YK, Call TG et al (2006) Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res 30:707–712CrossRefPubMed
7.
Zurück zum Zitat Shanafelt TD, Call TG, Zent CS et al (2009) Phase I trial of daily oral polyphenon E in patients with asymptomatic Rai Stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 27:3808–3814CrossRefPubMed Shanafelt TD, Call TG, Zent CS et al (2009) Phase I trial of daily oral polyphenon E in patients with asymptomatic Rai Stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 27:3808–3814CrossRefPubMed
8.
Zurück zum Zitat Rezai-Zadeh K, Shytle D, Sun N et al (2005) Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25:8807–8814CrossRefPubMed Rezai-Zadeh K, Shytle D, Sun N et al (2005) Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25:8807–8814CrossRefPubMed
9.
Zurück zum Zitat Lorenz M, Hellige N, Rieder P et al (2008) Positive inotropic effects of epigallocatechin-3-gallate (EGCG) involve activation of Na+/H+ and Na+/Ca2 + exchangers. Eur J Heart Fail 10:439–445CrossRefPubMed Lorenz M, Hellige N, Rieder P et al (2008) Positive inotropic effects of epigallocatechin-3-gallate (EGCG) involve activation of Na+/H+ and Na+/Ca2 + exchangers. Eur J Heart Fail 10:439–445CrossRefPubMed
10.
Zurück zum Zitat Hao J, Kim CH, Ha TS, Ahn HY (2007) Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats. J Vet Sci 8:121–129CrossRefPubMed Hao J, Kim CH, Ha TS, Ahn HY (2007) Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats. J Vet Sci 8:121–129CrossRefPubMed
11.
Zurück zum Zitat Ehrnhoefer DE, Bieschke J, Boeddrich A et al (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15:558–566CrossRefPubMed Ehrnhoefer DE, Bieschke J, Boeddrich A et al (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15:558–566CrossRefPubMed
12.
Zurück zum Zitat Hauber I, Hohenberg H, Holstermann B et al (2009) The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection. Proc Natl Acad Sci USA 106:9033–9038CrossRefPubMed Hauber I, Hohenberg H, Holstermann B et al (2009) The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection. Proc Natl Acad Sci USA 106:9033–9038CrossRefPubMed
13.
Zurück zum Zitat Mereles D, Wanker EE, Katus HA (2008) Therapy effects of green tea in a patient with systemic light-chain amyloidosis. Clin Res Cardiol 97:341–344CrossRefPubMed Mereles D, Wanker EE, Katus HA (2008) Therapy effects of green tea in a patient with systemic light-chain amyloidosis. Clin Res Cardiol 97:341–344CrossRefPubMed
14.
Zurück zum Zitat Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463CrossRefPubMed Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463CrossRefPubMed
15.
Zurück zum Zitat Nagueh SF, Appleton CP, Gillebert TC et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 22:107–133CrossRefPubMed Nagueh SF, Appleton CP, Gillebert TC et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 22:107–133CrossRefPubMed
16.
Zurück zum Zitat Yock PG, Popp RL (1984) Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 70:657–662PubMed Yock PG, Popp RL (1984) Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 70:657–662PubMed
17.
Zurück zum Zitat Ommen SR, Nishimura RA, Hurrel DG et al (2000) Assessment of right atrial pressure with 2-dimensional and Doppler-echocardiography: a simultaneous catheterization and echocardiography study. Mayo Clin Proc 75:24–29CrossRefPubMed Ommen SR, Nishimura RA, Hurrel DG et al (2000) Assessment of right atrial pressure with 2-dimensional and Doppler-echocardiography: a simultaneous catheterization and echocardiography study. Mayo Clin Proc 75:24–29CrossRefPubMed
18.
Zurück zum Zitat Levy D, Anderson KM, Savage DD et al (1988) Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 108:7–13PubMed Levy D, Anderson KM, Savage DD et al (1988) Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 108:7–13PubMed
19.
Zurück zum Zitat Siqueira-Filho AG, Cunha CL, Tajik AJ et al (1981) M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation 63:188–196PubMed Siqueira-Filho AG, Cunha CL, Tajik AJ et al (1981) M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation 63:188–196PubMed
20.
Zurück zum Zitat Hongo M, Ikeda S (1986) Echocardiographic assessment of the evolution of amyloid heart disease: a study with familial amyloid polyneuropathy. Circulation 73:249–256PubMed Hongo M, Ikeda S (1986) Echocardiographic assessment of the evolution of amyloid heart disease: a study with familial amyloid polyneuropathy. Circulation 73:249–256PubMed
21.
Zurück zum Zitat Klein AL, Hatle LK, Burstow DJ et al (1990) Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 15:99–108CrossRefPubMed Klein AL, Hatle LK, Burstow DJ et al (1990) Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 15:99–108CrossRefPubMed
22.
Zurück zum Zitat Klein AL, Hatle LK, Taliercio CP et al (1990) Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 16:1135–1141CrossRefPubMed Klein AL, Hatle LK, Taliercio CP et al (1990) Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 16:1135–1141CrossRefPubMed
23.
Zurück zum Zitat Bellavia D, Pellikka PA, Abraham TP et al (2008) Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol 101:1039–1045CrossRefPubMed Bellavia D, Pellikka PA, Abraham TP et al (2008) Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol 101:1039–1045CrossRefPubMed
24.
Zurück zum Zitat Palladini G, Lavatelli F, Russo P et al (2006) Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107:3854–3858CrossRefPubMed Palladini G, Lavatelli F, Russo P et al (2006) Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107:3854–3858CrossRefPubMed
25.
Zurück zum Zitat Jantunen E, Itälä M, Lehtinen T et al (2006) Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1,482 transplanted patients. Eur J Haematol 76:245–250CrossRefPubMed Jantunen E, Itälä M, Lehtinen T et al (2006) Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1,482 transplanted patients. Eur J Haematol 76:245–250CrossRefPubMed
26.
Zurück zum Zitat Robertson IM, Li MX, Sykes BD (2009) The solution structure of human cardiac troponin C in complex with the green tea polyphenol; (−)-epigallocatechin-3-gallate. J Biol Chem 284:23012–23023CrossRefPubMed Robertson IM, Li MX, Sykes BD (2009) The solution structure of human cardiac troponin C in complex with the green tea polyphenol; (−)-epigallocatechin-3-gallate. J Biol Chem 284:23012–23023CrossRefPubMed
27.
Zurück zum Zitat Liao R, Jain M, Teller P et al (2001) Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 104:1594–1597PubMed Liao R, Jain M, Teller P et al (2001) Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 104:1594–1597PubMed
28.
Zurück zum Zitat Sheng R, Gu ZL, Xie ML et al (2009) EGCG inhibits proliferation of cardiac fibroblasts in rats with cardiac hypertrophy. Planta Med 75:113–120CrossRefPubMed Sheng R, Gu ZL, Xie ML et al (2009) EGCG inhibits proliferation of cardiac fibroblasts in rats with cardiac hypertrophy. Planta Med 75:113–120CrossRefPubMed
29.
Zurück zum Zitat Grünig E, Janssen B, Mereles D et al (2000) Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation 102:1145–1150PubMed Grünig E, Janssen B, Mereles D et al (2000) Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation 102:1145–1150PubMed
30.
Zurück zum Zitat Henning SM, Niu Y, Liu Y et al (2005) Bioavailability and antioxidant effect of epigallocatechin gallate administered in purified form versus as green tea extract in healthy individuals. J Nutr Biochem 16:610–616CrossRefPubMed Henning SM, Niu Y, Liu Y et al (2005) Bioavailability and antioxidant effect of epigallocatechin gallate administered in purified form versus as green tea extract in healthy individuals. J Nutr Biochem 16:610–616CrossRefPubMed
31.
Zurück zum Zitat Chow HH, Hakim IA, Vining DR et al (2005) Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res 11:4627–4633CrossRefPubMed Chow HH, Hakim IA, Vining DR et al (2005) Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res 11:4627–4633CrossRefPubMed
Metadaten
Titel
Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis
Publikationsdatum
01.08.2010
Erschienen in
Clinical Research in Cardiology / Ausgabe 8/2010
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-010-0142-x

Weitere Artikel der Ausgabe 8/2010

Clinical Research in Cardiology 8/2010 Zur Ausgabe

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

24.04.2024 ACC 2024 Nachrichten

Eine FFR-gesteuerte komplette Revaskularisation war in einer Studie bei Patienten mit akutem Myokardinfarkt und koronarer Mehrgefäßerkrankung klinisch nicht wirksamer als eine alleinige Revaskularisation der Infarktarterie.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.